TNGX - NASDAQ
Tango Therapeutics, Inc.
$21.47
-7.1%Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.
At a Glance
Live Snapshottngx
Selling, General and Administrative Expenses
Last Annual Value
41.51M
3-Year CAGR
11%
5-Year CAGR
38%
10-Year CAGR
19%
Tango Therapeutics, Inc. Competitors Analysis of Selling, General and Administrative Expenses
| Company | Selling, General and Administrative Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Tango Therapeutics, Inc. NASDAQ:TNGX | 41.51M | 5.3% | 18.7% | N/A | |
 EyePoint Pharmaceuticals, Inc. NASDAQ:EYPT | 51.70M | -0.1% | -0.5% | 19.1% | |
 Kodiak Sciences Inc. NASDAQ:KOD | 52.02M | -9.9% | 4.9% | 32.6% | |
 UroGen Pharma Ltd. NASDAQ:URGN | 155.10M | 18.5% | N/A | 37.5% | |
 Kura Oncology, Inc. NASDAQ:KURA | 119.98M | 33.4% | 20.9% | 31.2% | |
 Nurix Therapeutics, Inc. NASDAQ:NRIX | 52.74M | 7.1% | 11.1% | N/A | |
 ProKidney Corp. NASDAQ:PROK | 51.78M | 4.9% | 42.4% | N/A | |
 Septerna, Inc. NASDAQ:SEPN | 29.16M | 44.2% | N/A | N/A | |
 Xencor, Inc. NASDAQ:XNCR | 63.64M | 6.0% | 10.4% | 17.1% | |
 Bicara Therapeutics Inc. Common Stock NASDAQ:BCAX | 30.51M | 48.7% | N/A | N/A | |
 Fortrea Holdings Inc. NASDAQ:FTRE | 456.40M | 0.6% | 8.5% | N/A |
Tango Therapeutics, Inc. Fair Value Envelope
Related Guides
Continue your TNGX research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.